Global Psychedelic Drugs Industry Outlook 2021: Overview, Opportunities, Key Companies and Forecast to 2027
Report Code: KNJ1027855 No. of Pages: 109 Category: Pharmaceuticals and Healthcare
Publisher: Date of Publish:
Publisher: Date of Publish:
Executive Summary
According to GRD Survey data, the global Psychedelic Drugs market was valued at million US$ in 2020 and is expected to million US$ by the end of 2027, growing at a CAGR of % in the forecast period 2021 and 2027.
This report studies the Psychedelic Drugs market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (Million USD) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
Geographically, this report is segmented into several key regions, with revenue, market share and growth Rate of Psychedelic Drugs in these regions, from 2016 to 2027, covering
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Italy, Spain and Russia, etc.)
Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)
Market Snapshot, By Product Type
Psilocybin
LSD
MDMA
DMT
Ketamine
Others
Market Snapshot, By Application
Depressive Disorders
Post-Traumatic Stress Disorders
Substance Abuse Disorders
Obsessive Compulsive Disorders
Others
Main Market Players Analyzed in this report, including:
Seelos Therapeutics
Revive Therapeutics
Red Light Holland
Pfizer
NUMINUS WELLNESS
Mydecine Innovations Group
MindMed
Mind Cure Health
Jannsen
Intellipharmaceutics
HAVN Life Sciences
GlaxoSmithKline
Field Trip Health
Entheon Biomedical
Eli Lilly
Cybin Inc
COMPASS Pathways PLC
Braxia Scientific
ATAI Life Sciences
Acadia Pharmaceuticals
The study objectives of this report are:
To study and analyze the global Psychedelic Drugs market size (Million USD) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.
To understand industry structure of Psychedelic Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To identify the key global Psychedelic Drugs manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Psychedelic Drugs market with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Psychedelic Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Psychedelic Drugs are as follows:
History Year: 2016-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2027
This report includes the estimation of market size from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources.
For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders Considered in the study:
Raw material vendors
Distributors/traders/wholesalers/suppliers
Regulatory authorities, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade/Industrial associations
End-use industries
Table of Contents
1 Market Definition & Scope
1.1 Definition & Scope
1.2 Psychedelic Drugs Product Specifications
1.3 Main Events (Entry, M&A, Exit, Technology and Capital Activity)
1.4 Global Psychedelic Drugs Market Performance and Outlook
2 Market Development Performance under COVID-19
2.1 Influencing Factors of Industry Development in the Next Five Years
2.1.1 Drivers
2.1.2 Restraints
2.1.3 Opportunities
2.2 Porter’s Five Forces Analysis
2.3 Comparison of Alternatives and Psychedelic Drugs
3 3 Industrial Lift Cycle and Main Buyers Analysis
3.1 Industry Life Cycle Analysis
3.2 Key Buying Industries/Consumers
3.2.1 Major Buyers in Depressive Disorders
3.2.2 Major Buyers in Post-Traumatic Stress Disorders
4 Market Segment: by Type
4.1 Psychedelic Drugs Type Introduction
4.1.1 Psilocybin
4.1.2 LSD
4.1.3 MDMA
4.1.4 DMT
4.1.5 Ketamine
4.1.6 Others
4.2 Global Psychedelic Drugs Revenue by Type 2016-2021
5 Market Segment: by Application
5.1 Psychedelic Drugs Type Introduction
5.1.1 Depressive Disorders
5.1.2 Post-Traumatic Stress Disorders
5.1.3 Substance Abuse Disorders
5.1.3 Obsessive Compulsive Disorders
5.1.4 Others
5.2 Global Psychedelic Drugs Revenue by Application 2016-2021
6 Marke Segment: by Region
6.1 Global Psychedelic Drugs Market by Region
6.2 North America Psychedelic Drugs Market 2016-2021
6.3 Europe Psychedelic Drugs Market 2016-2021
6.4 Asia Pacific Psychedelic Drugs Market 2016-2021
6.5 South America Psychedelic Drugs Market 2016-2021
6.6 Middle East and Africa Psychedelic Drugs Market 2016-2021
7 North America
7.1 North America Psychedelic Drugs Market by Country 2016-2021
7.2 United States
7.3 Canada
7.4 Mexico
8 Europe
8.1 Europe Psychedelic Drugs Market by Country 2016-2021
8.2 Germany
8.3 France
8.4 UK
8.5 Italy
8.6 Russia
8.7 Spain
9 Asia Pacific
9.1 Asia Pacific Psychedelic Drugs Market by Country 2016-2021
9.2 China
9.3 Japan
9.4 Korea
9.5 Southeast Asia
9.6 India
9.7 Australia
10 South America
10.1 South America Psychedelic Drugs Market by Country 2016-2021
10.2 Brazil
10.3 Argentina
10.4 Colombia
11 Middle East and Africa
11.1 Middle East and Africa Psychedelic Drugs Market by Country 2016-2021
11.2 Turkey
11.3 Saudi Arabia
11.4 South Africa
12 Key Participants Company Information
12.1 Seelos Therapeutics
12.1.1 Seelos Therapeutics
Company Information
12.1.2 Seelos Therapeutics
Psychedelic Drugs Product Portfolio, Specification and Application
12.1.3 Seelos Therapeutics
Psychedelic Drugs Revenue and Gross Margin (2019-2021)
12.1.4 Seelos Therapeutics
Key Development
12.2 Revive Therapeutics
12.2.1 Revive Therapeutics
Company Information
12.2.2 Revive Therapeutics
Psychedelic Drugs Product Portfolio, Specification and Application
12.2.3 Revive Therapeutics
Psychedelic Drugs Revenue and Gross Margin (2019-2021)
12.2.4 Revive Therapeutics
Key Development
12.3 Red Light Holland
12.3.1 Red Light Holland
Company Information
12.3.2 Red Light Holland
Psychedelic Drugs Product Portfolio, Specification and Application
12.3.3 Red Light Holland
Psychedelic Drugs Revenue and Gross Margin (2019-2021)
12.3.4 Red Light Holland
Key Development
12.4 Pfizer
12.4.1 Pfizer
Company Information
12.4.2 Pfizer
Psychedelic Drugs Product Portfolio, Specification and Application
12.4.3 Pfizer
Psychedelic Drugs Revenue and Gross Margin (2019-2021)
12.4.4 Pfizer
Key Development
12.5 NUMINUS WELLNESS
12.5.1 NUMINUS WELLNESS
Company Information
12.5.2 NUMINUS WELLNESS
Psychedelic Drugs Product Portfolio, Specification and Application
12.5.3 NUMINUS WELLNESS
Psychedelic Drugs Revenue and Gross Margin (2019-2021)
12.5.4 NUMINUS WELLNESS
Key Development
12.6 Mydecine Innovations Group
12.6.1 Mydecine Innovations Group
Company Information
12.6.2 Mydecine Innovations Group
Psychedelic Drugs Product Portfolio, Specification and Application
12.6.3 Mydecine Innovations Group
Psychedelic Drugs Revenue and Gross Margin (2019-2021)
12.6.4 Mydecine Innovations Group
Key Development
12.7 MindMed
12.7.1 MindMed
Company Information
12.7.2 MindMed
Psychedelic Drugs Product Portfolio, Specification and Application
12.7.3 MindMed
Psychedelic Drugs Revenue and Gross Margin (2019-2021)
12.7.4 Mydecine Innovations Group
Key Development
12.9 Jannsen
12.9.1 Jannsen
Company Information
12.9.2 Jannsen
Psychedelic Drugs Product Portfolio, Specification and Application
12.9.3 Jannsen
Psychedelic Drugs Revenue and Gross Margin (2019-2021)
12.9.4 Jannsen
Key Development
12.8 Mind Cure Health
12.8.1 Mind Cure Health
Company Information
12.8.2 Mind Cure Health
Psychedelic Drugs Product Portfolio, Specification and Application
12.8.3 Mind Cure Health
Psychedelic Drugs Revenue and Gross Margin (2019-2021)
12.8.4 Mind Cure Health
Key Development
12.11 HAVN Life Sciences
12.11.1 HAVN Life Sciences
Company Information
12.11.2 HAVN Life Sciences
Psychedelic Drugs Product Portfolio, Specification and Application
12.11.3 HAVN Life Sciences
Psychedelic Drugs Revenue and Gross Margin (2019-2021)
12.11.4 HAVN Life Sciences
Key Development
12.12 GlaxoSmithKline
12.12.1 GlaxoSmithKline
Company Information
12.12.2 GlaxoSmithKline
Psychedelic Drugs Product Portfolio, Specification and Application
12.12.3 GlaxoSmithKline
Psychedelic Drugs Revenue and Gross Margin (2019-2021)
12.12.4 GlaxoSmithKline
Key Development
12.13 Field Trip Health
12.13.1 Field Trip Health
Company Information
12.13.2 Field Trip Health
Psychedelic Drugs Product Portfolio, Specification and Application
12.13.3 Field Trip Health
Psychedelic Drugs Revenue and Gross Margin (2019-2021)
12.13.4 Field Trip Health
Key Development
12.14 Entheon Biomedical
12.14.1 Entheon Biomedical
Company Information
12.14.2 Entheon Biomedical
Psychedelic Drugs Product Portfolio, Specification and Application
12.14.3 Entheon Biomedical
Psychedelic Drugs Revenue and Gross Margin (2019-2021)
12.14.4 Entheon Biomedical
Key Development
12.15 Eli Lilly
12.15.1 Eli Lilly
Company Information
12.15.2 Eli Lilly
Psychedelic Drugs Product Portfolio, Specification and Application
12.15.3 Eli Lilly
Psychedelic Drugs Revenue and Gross Margin (2019-2021)
12.15.4 Eli Lilly
Key Development
12.17 COMPASS Pathways PLC
12.18 Braxia Scientific
12.19 ATAI Life Sciences
12.20 Acadia Pharmaceuticals
13 Global Psychedelic Drugs Market Forecast by Region by Type and by Application
13.1 Global Psychedelic Drugs Revenue Forecast 2022-2027
13.2 Global Psychedelic Drugs Forecast by Regions
13.3 Global Psychedelic Drugs Forecast by Type
13.4 Global Psychedelic Drugs Forecast by Application
14 Analyst Views and Conclusions
15 Methodology and Data Source
15.1 Methodology
15.2 Research Data Source
15.2.1 Secondary Data
15.2.2 Primary Data
15.2.3 Market Size Estimation
15.3 Legal Disclaimer
NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com